Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Analysis of Nkx3.1:Cre-driven Erk5 deletion reveals a profound spinal deformity which is linked to increased osteoclast activity.

Loveridge CJ, van 't Hof RJ, Charlesworth G, King A, Tan EH, Rose L, Daroszewska A, Prior A, Ahmad I, Welsh M, Mui EJ, Ford C, Salji M, Sansom O, Blyth K, Leung HY.

Sci Rep. 2017 Oct 16;7(1):13241. doi: 10.1038/s41598-017-13346-8.

2.

Increased T-cell Infiltration Elicited by Erk5 Deletion in a Pten-Deficient Mouse Model of Prostate Carcinogenesis.

Loveridge CJ, Mui EJ, Patel R, Tan EH, Ahmad I, Welsh M, Galbraith J, Hedley A, Nixon C, Blyth K, Sansom O, Leung HY.

Cancer Res. 2017 Jun 15;77(12):3158-3168. doi: 10.1158/0008-5472.CAN-16-2565. Epub 2017 May 17.

3.

Design, synthesis, and biological activity of diaryl ether inhibitors of Toxoplasma gondii enoyl reductase.

Cheng G, Muench SP, Zhou Y, Afanador GA, Mui EJ, Fomovska A, Lai BS, Prigge ST, Woods S, Roberts CW, Hickman MR, Lee PJ, Leed SE, Auschwitz JM, Rice DW, McLeod R.

Bioorg Med Chem Lett. 2013 Apr 1;23(7):2035-43. doi: 10.1016/j.bmcl.2013.02.019. Epub 2013 Feb 13.

4.

Novel N-benzoyl-2-hydroxybenzamide disrupts unique parasite secretory pathway.

Fomovska A, Huang Q, El Bissati K, Mui EJ, Witola WH, Cheng G, Zhou Y, Sommerville C, Roberts CW, Bettis S, Prigge ST, Afanador GA, Hickman MR, Lee PJ, Leed SE, Auschwitz JM, Pieroni M, Stec J, Muench SP, Rice DW, Kozikowski AP, McLeod R.

Antimicrob Agents Chemother. 2012 May;56(5):2666-82. doi: 10.1128/AAC.06450-11. Epub 2012 Feb 21.

5.

Toxoplasma gondii HLA-B*0702-restricted GRA7(20-28) peptide with adjuvants and a universal helper T cell epitope elicits CD8(+) T cells producing interferon-γ and reduces parasite burden in HLA-B*0702 mice.

Cong H, Mui EJ, Witola WH, Sidney J, Alexander J, Sette A, Maewal A, El Bissati K, Zhou Y, Suzuki Y, Lee D, Woods S, Sommerville C, Henriquez FL, Roberts CW, McLeod R.

Hum Immunol. 2012 Jan;73(1):1-10. doi: 10.1016/j.humimm.2011.10.006. Epub 2011 Oct 12.

7.

Towards an immunosense vaccine to prevent toxoplasmosis: protective Toxoplasma gondii epitopes restricted by HLA-A*0201.

Cong H, Mui EJ, Witola WH, Sidney J, Alexander J, Sette A, Maewal A, McLeod R.

Vaccine. 2011 Jan 17;29(4):754-62. doi: 10.1016/j.vaccine.2010.11.015. Epub 2010 Nov 21.

8.

Identification and development of novel inhibitors of Toxoplasma gondii enoyl reductase.

Tipparaju SK, Muench SP, Mui EJ, Ruzheinikov SN, Lu JZ, Hutson SL, Kirisits MJ, Prigge ST, Roberts CW, Henriquez FL, Kozikowski AP, Rice DW, McLeod RL.

J Med Chem. 2010 Sep 9;53(17):6287-300. doi: 10.1021/jm9017724.

9.

Evidence for associations between the purinergic receptor P2X(7) (P2RX7) and toxoplasmosis.

Jamieson SE, Peixoto-Rangel AL, Hargrave AC, Roubaix LA, Mui EJ, Boulter NR, Miller EN, Fuller SJ, Wiley JS, Castellucci L, Boyer K, Peixe RG, Kirisits MJ, Elias Lde S, Coyne JJ, Correa-Oliveira R, Sautter M, Smith NC, Lees MP, Swisher CN, Heydemann P, Noble AG, Patel D, Bardo D, Burrowes D, McLone D, Roizen N, Withers S, Bahia-Oliveira LM, McLeod R, Blackwell JM.

Genes Immun. 2010 Jul;11(5):374-83. doi: 10.1038/gene.2010.31. Epub 2010 Jun 10.

10.

P2X7 receptor-mediated killing of an intracellular parasite, Toxoplasma gondii, by human and murine macrophages.

Lees MP, Fuller SJ, McLeod R, Boulter NR, Miller CM, Zakrzewski AM, Mui EJ, Witola WH, Coyne JJ, Hargrave AC, Jamieson SE, Blackwell JM, Wiley JS, Smith NC.

J Immunol. 2010 Jun 15;184(12):7040-6. doi: 10.4049/jimmunol.1000012. Epub 2010 May 19.

11.

Genetic and epigenetic factors at COL2A1 and ABCA4 influence clinical outcome in congenital toxoplasmosis.

Jamieson SE, de Roubaix LA, Cortina-Borja M, Tan HK, Mui EJ, Cordell HJ, Kirisits MJ, Miller EN, Peacock CS, Hargrave AC, Coyne JJ, Boyer K, Bessieres MH, Buffolano W, Ferret N, Franck J, Kieffer F, Meier P, Nowakowska DE, Paul M, Peyron F, Stray-Pedersen B, Prusa AR, Thulliez P, Wallon M, Petersen E, McLeod R, Gilbert RE, Blackwell JM.

PLoS One. 2008 Jun 4;3(6):e2285. doi: 10.1371/journal.pone.0002285.

12.

Novel triazine JPC-2067-B inhibits Toxoplasma gondii in vitro and in vivo.

Mui EJ, Schiehser GA, Milhous WK, Hsu H, Roberts CW, Kirisits M, Muench S, Rice D, Dubey JP, Fowble JW, Rathod PK, Queener SF, Liu SR, Jacobus DP, McLeod R.

PLoS Negl Trop Dis. 2008 Mar 5;2(3):e190. doi: 10.1371/journal.pntd.0000190.

13.

Studies of Toxoplasma gondii and Plasmodium falciparum enoyl acyl carrier protein reductase and implications for the development of antiparasitic agents.

Muench SP, Prigge ST, McLeod R, Rafferty JB, Kirisits MJ, Roberts CW, Mui EJ, Rice DW.

Acta Crystallogr D Biol Crystallogr. 2007 Mar;63(Pt 3):328-38. Epub 2007 Feb 21.

14.

Triazine Inhibits Toxoplasma gondii tachyzoites in vitro and in vivo.

Mui EJ, Jacobus D, Milhous WK, Schiehser G, Hsu H, Roberts CW, Kirisits MJ, McLeod R.

Antimicrob Agents Chemother. 2005 Aug;49(8):3463-7.

15.

A complete shikimate pathway in Toxoplasma gondii: an ancient eukaryotic innovation.

Campbell SA, Richards TA, Mui EJ, Samuel BU, Coggins JR, McLeod R, Roberts CW.

Int J Parasitol. 2004 Jan;34(1):5-13.

PMID:
14711585
16.

The shikimate pathway and its branches in apicomplexan parasites.

Roberts CW, Roberts F, Lyons RE, Kirisits MJ, Mui EJ, Finnerty J, Johnson JJ, Ferguson DJ, Coggins JR, Krell T, Coombs GH, Milhous WK, Kyle DE, Tzipori S, Barnwell J, Dame JB, Carlton J, McLeod R.

J Infect Dis. 2002 Feb 15;185 Suppl 1:S25-36. Review.

PMID:
11865437
17.

Triclosan inhibits the growth of Plasmodium falciparum and Toxoplasma gondii by inhibition of apicomplexan Fab I.

McLeod R, Muench SP, Rafferty JB, Kyle DE, Mui EJ, Kirisits MJ, Mack DG, Roberts CW, Samuel BU, Lyons RE, Dorris M, Milhous WK, Rice DW.

Int J Parasitol. 2001 Feb;31(2):109-13.

PMID:
11239932

Supplemental Content

Support Center